Kurzfassung

The combination of FGFR2 blockade with PD-1 inhibition might offer improved immunological benefits. That is why a combination of Futibatinib with anti-PD-1 checkpoint inhibitors would be beneficial. In this project we precisely analyze the immunological effects of Futibatinib +/- anti-PD 1mAb in different immune cells co-cultured with human gastric cancer cells. Comparison of FGFR2 negative and FGFR2 amplificated gastric cancer cells offers the discrimination between responder and...The combination of FGFR2 blockade with PD-1 inhibition might offer improved immunological benefits. That is why a combination of Futibatinib with anti-PD-1 checkpoint inhibitors would be beneficial. In this project we precisely analyze the immunological effects of Futibatinib +/- anti-PD 1mAb in different immune cells co-cultured with human gastric cancer cells. Comparison of FGFR2 negative and FGFR2 amplificated gastric cancer cells offers the discrimination between responder and non-responder and give a deeper insight if expression on immune or gastric cancer cells play the decisive role. With innovative combinations of Futibatinib including anti PD-L1 or anti PD-1 mAb, we will overcome FGFR induced tumor growth, block therapeutic resistance and reduce immune cell silencing.» weiterlesen» einklappen